Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
Active, not recruiting · NCT06665412 · Registry updated 2026-09-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML | Chronic Phase Ph+ Chronic Myeloid Leukemia | Active, not recruiting | Not stated | 2026-09-03 | NCT06665412 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Il-Yang Pharm. Co., Ltd. | 6 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hallym University Sacred Heart Hosptial | Anyang-si | South Korea | 1 |
| Keimyung University Daegu Dongsan Hospital | Daegu | South Korea | 1 |